First UPC decision to tackle infringement and validity of second medical claims (Sanofi v Amgen, UPC_CFI_505/2024) By Dr Rose Hughes at Monday, May 19, 2025 IPKat PatKat Rose Hughes. unitary patent court Second medical use upc +
[Guest Post] Exhaustion of Trade Mark Rights and the Burden of Proof: Coty/Easycosmetic By Marcel Pemsel at Friday, May 16, 2025 Coty Diego Guerrero Obando exhaustion parallel trade trade marks +
Government announces that UK+ IP exhaustion regime is here to stay By Jocelyn Bosse at Thursday, May 15, 2025 Brexit European Economic Area exhaustion Jocelyn Bosse parallel imports +
Never Too Late: If you missed the IPKat last week! By Asude Sena Moya at Wednesday, May 14, 2025 #NeverTooLate AI Artificial Intelligence Asude Sena Moya Boards of Appeal copyright designs events General Court opportunities originality patent litigation patents trade marks +
Defining the undefinable: The challenges and opportunities for cell therapy IP By Dr Rose Hughes at Tuesday, May 13, 2025 cell therapy ip strategy patents PatKat pharma ip Rose Hughes +
AI and Copyright - the Kidron Amendments By Oliver Fairhurst at Tuesday, May 13, 2025 AI Artificial Intelligence copyright Oliver Fairhurst uk parliament +
The never-ending story of Brexit – Chapter: EUIPO v Nowhere – Act I: The Advocate General’s Opinion By Marcel Pemsel at Tuesday, May 13, 2025 Advocate General Ape Tees Brexit C-337/22 Marcel Pemsel Nowhere trade marks +
[Guest Post] A shotgun revocation? Did the South African court jump the gun in Regents of the University of California v Eurolab & Dis-Chem? By Simone Lorenzi at Monday, May 12, 2025 Adanna Onah Guest post patents +
[Guest Post] Out the Door, Back In Through the Grille: Warsaw Court Reverses Audi Advantage By Marcel Pemsel at Sunday, May 11, 2025 Audi C-334/22 CJEU due cause Luigi Manna spare parts trade marks +
UK court reaffirms its stringent plausibility standard in AstraZeneca despite G 2/21 By Annsley Merelle Ward at Friday, May 09, 2025 #IPKat AstraZeneca epc G 2/21 Michael Tappin QC patent litigation plausibility SPC sufficiency Teva UK +